首页 > 最新文献

Cancer Epidemiology Biomarkers & Prevention最新文献

英文 中文
Treatment and survival differences between patients with invasive lobular carcinoma versus invasive ductal carcinoma of the breast. 浸润性乳腺小叶癌与浸润性乳腺导管癌患者的治疗和生存率差异。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-24 DOI: 10.1158/1055-9965.EPI-24-1250
Jesus D Anampa, Shuwen Lin, Samilia Obeng-Gyasi, Xiaonan Xue

Background: Invasive lobular carcinoma (ILC) exhibits differences in molecular and biological characteristics compared to invasive ductal carcinoma (IDC). We aim to compare breast cancer-specific survival (BCSS) between patients with ILC and IDC.

Methods: We used data from the Surveillance, Epidemiology, and End Results database (1992-2020). Logistic regression analyses were conducted to identify factors associated with treatment modalities. We examined BCSS at different time points using a cox regression model with time-dependent coefficient.

Results: 343,397 patients with IDC and 39,859 patients with ILC were included. Patients with ILC had more advanced stage disease (stage II, 35% vs. 34%; stage III, 16% vs.11%), and higher rate of hormone receptor-positive disease (97% vs. 81%). Compared to patients with IDC, patients with ILC had better BCSS in the first five years (Hazard ratio [HR]=0.71, p <0.001), but worse BCSS in later years (HR=1.30, p<0.001 in year 6-10; HR=1.75, p<0.001 in year 11-15; HR=2.17, p<0.001 in year 16-20).

Conclusions: Patients with ILC survive better in early years but worse in later years compared to patients with IDC. Future studies are required to identify patients with ILC who are at risk of late recurrence or mortality.

Impact: The results of this study add to the currently conflicting literature of survival of ILC and demonstrate the importance of evaluating novel therapeutic approaches and extended therapy for patients with ILC.

背景:浸润性小叶癌(ILC)与浸润性导管癌(IDC)相比,在分子和生物学特征方面存在差异。我们旨在比较ILC和IDC患者的乳腺癌特异性生存率(BCSS):我们使用了监测、流行病学和最终结果数据库(1992-2020 年)中的数据。我们进行了逻辑回归分析,以确定与治疗方式相关的因素。我们使用具有时间依赖性系数的考克斯回归模型研究了不同时间点的 BCSS:共纳入 343,397 例 IDC 患者和 39,859 例 ILC 患者。ILC患者的疾病分期更晚(II期,35%对34%;III期,16%对11%),激素受体阳性率更高(97%对81%)。与IDC患者相比,ILC患者在前五年的BCSS较好(危险比[HR]=0.71,P 结论:ILC患者在早期存活率较高:与IDC患者相比,ILC患者早年存活率更高,但晚年存活率更低。未来的研究需要确定哪些 ILC 患者有晚期复发或死亡的风险:本研究结果补充了目前关于ILC存活率的相互矛盾的文献,并证明了评估新型治疗方法和延长ILC患者治疗时间的重要性。
{"title":"Treatment and survival differences between patients with invasive lobular carcinoma versus invasive ductal carcinoma of the breast.","authors":"Jesus D Anampa, Shuwen Lin, Samilia Obeng-Gyasi, Xiaonan Xue","doi":"10.1158/1055-9965.EPI-24-1250","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1250","url":null,"abstract":"<p><strong>Background: </strong>Invasive lobular carcinoma (ILC) exhibits differences in molecular and biological characteristics compared to invasive ductal carcinoma (IDC). We aim to compare breast cancer-specific survival (BCSS) between patients with ILC and IDC.</p><p><strong>Methods: </strong>We used data from the Surveillance, Epidemiology, and End Results database (1992-2020). Logistic regression analyses were conducted to identify factors associated with treatment modalities. We examined BCSS at different time points using a cox regression model with time-dependent coefficient.</p><p><strong>Results: </strong>343,397 patients with IDC and 39,859 patients with ILC were included. Patients with ILC had more advanced stage disease (stage II, 35% vs. 34%; stage III, 16% vs.11%), and higher rate of hormone receptor-positive disease (97% vs. 81%). Compared to patients with IDC, patients with ILC had better BCSS in the first five years (Hazard ratio [HR]=0.71, p <0.001), but worse BCSS in later years (HR=1.30, p<0.001 in year 6-10; HR=1.75, p<0.001 in year 11-15; HR=2.17, p<0.001 in year 16-20).</p><p><strong>Conclusions: </strong>Patients with ILC survive better in early years but worse in later years compared to patients with IDC. Future studies are required to identify patients with ILC who are at risk of late recurrence or mortality.</p><p><strong>Impact: </strong>The results of this study add to the currently conflicting literature of survival of ILC and demonstrate the importance of evaluating novel therapeutic approaches and extended therapy for patients with ILC.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of developing a subsequent primary cancer among adult cancer survivors. 成年癌症幸存者罹患后续原发性癌症的风险。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1158/1055-9965.EPI-24-0636
Matthew T Warkentin, Winson Y Cheung, Darren R Brenner, Dylan E O'Sullivan

Background: Improvements in cancer control have led to a drastic increase in cancer survivors who may be at an elevated risk of developing subsequent primary cancers (SPC). In this study, we assessed the risk and patterns of SPC development among 196,858 adult cancer survivors in Alberta, Canada.

Methods: We used data from the Alberta Cancer Registry to identify all first primary cancers occurring between 2004 and 2020. A SPC was considered as the next primary cancer occurring in a different site. We estimated standardized incidence ratios (SIR) for SPC development as the observed number of SPC (O) divided by the expected number of SPC (E), where E is a weighted-sum of the population-based year-age-sex-specific incidence rates and the corresponding person-years of follow-up.

Results: The risk of developing a SPC up to fifteen years after an initial cancer was 16.2% for males and 12.2% for females. Overall, both males (SIR=1.50) and females (SIR=1.58) had an increased risk of a SPC. There were significant increases in SPC risk for nearly all age groups, with a greater than 5-fold increase for survivors diagnosed between ages 18-39. Screen-detectable cancers including colorectal, lung, cervix, and breast accounted for 46% and 27% of SPCs among females and males.

Conclusions: Cancer survivors of nearly every initial site had substantially increased risk of a SPC, compared to the cancer risk in the general population.

Impact: Screen-detectable cancers were common SPC sites and highlights the need to investigate optimal strategies for screening the growing population of cancer survivors.

背景:随着癌症控制水平的提高,癌症幸存者的人数急剧增加,他们罹患后续原发性癌症(SPC)的风险也随之升高。在这项研究中,我们评估了加拿大艾伯塔省 196,858 名成年癌症幸存者罹患 SPC 的风险和模式:我们利用艾伯塔省癌症登记处的数据,确定了 2004 年至 2020 年间发生的所有首次原发性癌症。SPC被认为是发生在不同部位的下一次原发性癌症。我们用观察到的SPC数量(O)除以预期的SPC数量(E)来估算SPC发病的标准化发病率(SIR),其中E是基于人口的年-性别特异性发病率和相应的随访人-年的加权和:在初次患癌后十五年内,男性罹患 SPC 的风险为 16.2%,女性为 12.2%。总体而言,男性(SIR=1.50)和女性(SIR=1.58)罹患 SPC 的风险都有所增加。几乎所有年龄组的 SPC 风险都明显增加,18-39 岁之间确诊的幸存者的 SPC 风险增加了 5 倍多。筛查出的癌症包括结直肠癌、肺癌、宫颈癌和乳腺癌,分别占女性和男性SPC的46%和27%:结论:与普通人群的癌症风险相比,几乎所有初始部位的癌症幸存者患 SPC 的风险都大大增加:影响:可筛查出的癌症是常见的 SPC 病变部位,这表明有必要研究筛查不断增长的癌症幸存者人群的最佳策略。
{"title":"Risk of developing a subsequent primary cancer among adult cancer survivors.","authors":"Matthew T Warkentin, Winson Y Cheung, Darren R Brenner, Dylan E O'Sullivan","doi":"10.1158/1055-9965.EPI-24-0636","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0636","url":null,"abstract":"<p><strong>Background: </strong>Improvements in cancer control have led to a drastic increase in cancer survivors who may be at an elevated risk of developing subsequent primary cancers (SPC). In this study, we assessed the risk and patterns of SPC development among 196,858 adult cancer survivors in Alberta, Canada.</p><p><strong>Methods: </strong>We used data from the Alberta Cancer Registry to identify all first primary cancers occurring between 2004 and 2020. A SPC was considered as the next primary cancer occurring in a different site. We estimated standardized incidence ratios (SIR) for SPC development as the observed number of SPC (O) divided by the expected number of SPC (E), where E is a weighted-sum of the population-based year-age-sex-specific incidence rates and the corresponding person-years of follow-up.</p><p><strong>Results: </strong>The risk of developing a SPC up to fifteen years after an initial cancer was 16.2% for males and 12.2% for females. Overall, both males (SIR=1.50) and females (SIR=1.58) had an increased risk of a SPC. There were significant increases in SPC risk for nearly all age groups, with a greater than 5-fold increase for survivors diagnosed between ages 18-39. Screen-detectable cancers including colorectal, lung, cervix, and breast accounted for 46% and 27% of SPCs among females and males.</p><p><strong>Conclusions: </strong>Cancer survivors of nearly every initial site had substantially increased risk of a SPC, compared to the cancer risk in the general population.</p><p><strong>Impact: </strong>Screen-detectable cancers were common SPC sites and highlights the need to investigate optimal strategies for screening the growing population of cancer survivors.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying measures for understanding and addressing county-level disparities in adolescent HPV vaccination coverage in North Carolina. 确定了解和解决北卡罗来纳州青少年 HPV 疫苗接种覆盖率县级差距的措施。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-17 DOI: 10.1158/1055-9965.EPI-24-1186
Brigid K Grabert, Mary Catharine McKeithen, Justin G Trogdon, Lisa P Spees, Stephanie B Wheeler, Jenny K Myers, Jennifer C Spencer, Melissa B Gilkey

Background: HPV vaccination coverage is characterized by geographic disparities in the US, with national studies finding lower coverage in rural versus nonrural areas. To direct quality improvement efforts in North Carolina, we sought to understand how different rurality measures characterize these disparities.

Methods: We used separate negative binomial regression models to test associations between 5 dichotomized county-level rurality measures and HPV vaccination coverage (≥1 dose) among North Carolina adolescents, ages 11-12 (n=326,345). Rurality measures were derived from: Office of Management and Budget's Metropolitan Statistical Areas, Rural-Urban Continuum Codes, Index of Relative Rurality, US Census Bureau classifications, and North Carolina Rural Center classifications. Models controlled for Social Vulnerability Index (SVI) percentile and rate of pediatricians per county. Vaccination data came from the North Carolina Immunization Registry.

Results: HPV vaccination coverage was 29% across North Carolina's 100 counties (range: 13%, 46%). Agreement between rurality measures ranged from 54% to 93% of counties. In adjusted analyses, none of the 5 rurality measures correlated with HPV vaccination coverage, but higher SVI and higher rate of pediatricians were positively associated with coverage (p< 0.01). Exploratory moderation analyses suggested regional variation in the relationship between rurality and coverage, with a positive association in one region, a negative association in one region, and no association in four regions.

Conclusions: County-level rurality measures did not identify disparities in HPV vaccination coverage in North Carolina.

Impact: Measures related to social vulnerability and access to pediatricians may be better suited for understanding and addressing the state's substantial county-level vaccination disparities.

背景:在美国,HPV 疫苗接种覆盖率存在地域差异,全国性研究发现农村地区的覆盖率低于非农村地区。为了指导北卡罗来纳州的质量改进工作,我们试图了解不同的农村地区衡量标准是如何描述这些差异的:我们使用了单独的负二项回归模型来检验北卡罗来纳州 11-12 岁青少年(n=326,345)中 5 个二分法县级农村测量值与 HPV 疫苗接种覆盖率(≥1 剂)之间的关联。乡镇化指标来源于:管理和预算办公室的大都市统计区、农村-城市连续代码、相对乡镇化指数、美国人口普查局分类以及北卡罗来纳州乡镇中心分类。模型控制了社会弱势指数 (SVI) 百分位数和每个县的儿科医生比例。疫苗接种数据来自北卡罗来纳州免疫登记处:北卡罗来纳州 100 个县的 HPV 疫苗接种覆盖率为 29%(范围:13%-46%)。各县之间的乡土性测量结果一致率从 54% 到 93% 不等。在调整后的分析中,5 个乡镇测量指标均与 HPV 疫苗接种覆盖率无关,但较高的 SVI 和较高的儿科医生比例与覆盖率呈正相关(p< 0.01)。探索性调节分析表明,乡土性与覆盖率之间的关系存在地区差异,一个地区呈正相关,一个地区呈负相关,四个地区无相关:结论:县级农村地区的衡量标准并不能确定北卡罗来纳州 HPV 疫苗接种覆盖率的差异:影响:与社会脆弱性和获得儿科医生服务相关的措施可能更适合用于了解和解决该州县级疫苗接种率的巨大差异。
{"title":"Identifying measures for understanding and addressing county-level disparities in adolescent HPV vaccination coverage in North Carolina.","authors":"Brigid K Grabert, Mary Catharine McKeithen, Justin G Trogdon, Lisa P Spees, Stephanie B Wheeler, Jenny K Myers, Jennifer C Spencer, Melissa B Gilkey","doi":"10.1158/1055-9965.EPI-24-1186","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-1186","url":null,"abstract":"<p><strong>Background: </strong>HPV vaccination coverage is characterized by geographic disparities in the US, with national studies finding lower coverage in rural versus nonrural areas. To direct quality improvement efforts in North Carolina, we sought to understand how different rurality measures characterize these disparities.</p><p><strong>Methods: </strong>We used separate negative binomial regression models to test associations between 5 dichotomized county-level rurality measures and HPV vaccination coverage (≥1 dose) among North Carolina adolescents, ages 11-12 (n=326,345). Rurality measures were derived from: Office of Management and Budget's Metropolitan Statistical Areas, Rural-Urban Continuum Codes, Index of Relative Rurality, US Census Bureau classifications, and North Carolina Rural Center classifications. Models controlled for Social Vulnerability Index (SVI) percentile and rate of pediatricians per county. Vaccination data came from the North Carolina Immunization Registry.</p><p><strong>Results: </strong>HPV vaccination coverage was 29% across North Carolina's 100 counties (range: 13%, 46%). Agreement between rurality measures ranged from 54% to 93% of counties. In adjusted analyses, none of the 5 rurality measures correlated with HPV vaccination coverage, but higher SVI and higher rate of pediatricians were positively associated with coverage (p< 0.01). Exploratory moderation analyses suggested regional variation in the relationship between rurality and coverage, with a positive association in one region, a negative association in one region, and no association in four regions.</p><p><strong>Conclusions: </strong>County-level rurality measures did not identify disparities in HPV vaccination coverage in North Carolina.</p><p><strong>Impact: </strong>Measures related to social vulnerability and access to pediatricians may be better suited for understanding and addressing the state's substantial county-level vaccination disparities.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in Breast Cancer Screening Prevalence in the US During the COVID-19 Pandemic, 2018-2022. 2018-2022 年 COVID-19 大流行期间美国乳腺癌筛查流行率的变化。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-15 DOI: 10.1158/1055-9965.EPI-24-0540
Kilan C Ashad-Bishop, Jessica Star, Angela N Giaquinto, Robert A Smith, Ahmedin Jemal, Priti Bandi

Background: Annual mammography screening declined year-on-year during the COVID-19 pandemic through 2021. This study examined changes in 2022 compared to 2018 in the national prevalence of self-reported up-to-date mammography.

Methods: Using 2018-2022 data from the Center for Disease Control and Prevention's (CDC) Behavioral Risk Factor Surveillance System (BRFSS), we assess relative changes defined as annual prevalence ratios (aPR) in the SR receipt of past-year and up-to-date (UTD) breast cancer screening (bi-annual mammography in women ages 50-74 years) during the third year of the COVID-19 pandemic overall and by sociodemographic characteristics.

Results: UTD BC screening declined for the first time since 2018 (2018 compared to 2022, from 78.7% to 76.6%; aPR, 0.97; 95% CI, 0.96-0.98), despite a small increase in past-year breast cancer screening from 2020 and 2022 (57.9% to 59.6%; aPR, 1.03; 95% CI, 1.01-1.05). This translated to 747,791 fewer women reporting UTD with recommended BC screening in 2022 vs. 2018. UTD BC screening declines between 2018-2022 were largest for American Indian/Alaska Native women (74.8% to 62.2%; aPR, 0.83; 95% CI, 0.74-0.93), women with less formal educational attainment (< high school: 73.1% to 65.5%; aPR, 0.9; 95% CI, 0.85-0.95), and women without a usual source of care (48% to 42.9%; aPR, 0.85; 95% CI, 0.78-0.92).

Conclusions: Previously noted pandemic-related declines in past-year BC screening now reflect in women reporting being UTD, with the largest declines in AI/AN and lower SES women.

Impact: Future studies should monitor screening prevalence in relation to BC diagnostic stage, overall and by sociodemographic groups.

背景:在COVID-19大流行期间至2021年,乳腺X线照相术年筛查率逐年下降。本研究考察了 2022 年与 2018 年相比,全国自我报告的最新乳腺放射摄影流行率的变化情况:利用疾病控制和预防中心(CDC)行为风险因素监测系统(BRFSS)提供的2018-2022年数据,我们评估了COVID-19大流行第三年期间SR接受过去一年和最新(UTD)乳腺癌筛查(50-74岁女性一年两次乳房X线照相术)的相对变化(定义为年流行率比(aPR)):自2018年以来,UTD BC筛查率首次下降(2018年与2022年相比,从78.7%降至76.6%;aPR,0.97;95% CI,0.96-0.98),尽管从2020年到2022年,上一年的乳腺癌筛查率略有增加(57.9%增至59.6%;aPR,1.03;95% CI,1.01-1.05)。这意味着 2022 年与 2018 年相比,报告UTD 接受建议 BC 筛查的女性人数减少了 747 791 人。2018-2022年期间,美国印第安人/阿拉斯加原住民妇女(74.8%降至62.2%;aPR,0.83;95% CI,0.74-0.93)、正规教育程度较低的妇女(<高中:73.1%降至65.5%;aPR,0.9;95% CI,0.85-0.95)和没有惯常护理来源的妇女(48%降至42.9%;aPR,0.85;95% CI,0.78-0.92)的UTD BC筛查下降幅度最大:结论:之前注意到的与大流行相关的上一年 BC 筛查率的下降现在反映在报告未接受筛查的女性中,其中下降幅度最大的是亚裔美国人/印第安人和社会经济地位较低的女性:影响:未来的研究应监测筛查流行率与 BC 诊断阶段的关系,包括总体流行率和社会人口群体流行率。
{"title":"Changes in Breast Cancer Screening Prevalence in the US During the COVID-19 Pandemic, 2018-2022.","authors":"Kilan C Ashad-Bishop, Jessica Star, Angela N Giaquinto, Robert A Smith, Ahmedin Jemal, Priti Bandi","doi":"10.1158/1055-9965.EPI-24-0540","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0540","url":null,"abstract":"<p><strong>Background: </strong>Annual mammography screening declined year-on-year during the COVID-19 pandemic through 2021. This study examined changes in 2022 compared to 2018 in the national prevalence of self-reported up-to-date mammography.</p><p><strong>Methods: </strong>Using 2018-2022 data from the Center for Disease Control and Prevention's (CDC) Behavioral Risk Factor Surveillance System (BRFSS), we assess relative changes defined as annual prevalence ratios (aPR) in the SR receipt of past-year and up-to-date (UTD) breast cancer screening (bi-annual mammography in women ages 50-74 years) during the third year of the COVID-19 pandemic overall and by sociodemographic characteristics.</p><p><strong>Results: </strong>UTD BC screening declined for the first time since 2018 (2018 compared to 2022, from 78.7% to 76.6%; aPR, 0.97; 95% CI, 0.96-0.98), despite a small increase in past-year breast cancer screening from 2020 and 2022 (57.9% to 59.6%; aPR, 1.03; 95% CI, 1.01-1.05). This translated to 747,791 fewer women reporting UTD with recommended BC screening in 2022 vs. 2018. UTD BC screening declines between 2018-2022 were largest for American Indian/Alaska Native women (74.8% to 62.2%; aPR, 0.83; 95% CI, 0.74-0.93), women with less formal educational attainment (< high school: 73.1% to 65.5%; aPR, 0.9; 95% CI, 0.85-0.95), and women without a usual source of care (48% to 42.9%; aPR, 0.85; 95% CI, 0.78-0.92).</p><p><strong>Conclusions: </strong>Previously noted pandemic-related declines in past-year BC screening now reflect in women reporting being UTD, with the largest declines in AI/AN and lower SES women.</p><p><strong>Impact: </strong>Future studies should monitor screening prevalence in relation to BC diagnostic stage, overall and by sociodemographic groups.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physical activity during adolescence and early adulthood and breast cancer risk before age 40 years. 青春期和成年早期的体育锻炼与 40 岁前患乳腺癌的风险。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-15 DOI: 10.1158/1055-9965.EPI-24-0743
Rebecca D Kehm, Jeanine M Genkinger, Julia A Knight, Robert J Maclnnis, Yuyan Liao, Shuai Li, Prue C Weideman, Wendy K Chung, Allison W Kurian, Sarah V Colonna, Irene L Andrulis, Saundra S Buys, Mary B Daly, Esther M John, John L Hopper, Mary Beth Terry

Background: Breast cancer (BC) incidence is increasing in women under age 40 years, underscoring the need for research on BC risk factors for younger women.

Methods: We used data from an international family cohort (n=26,348) to examine whether recreational physical activity (RPA) during adolescence and early adulthood are associated with BC risk before age 40. The cohort includes 2,502 women diagnosed with BC before age 40, including 2,408 diagnosed before study enrollment (68% within 5 years of enrollment). Women reported their average hours-per-week of moderate and strenuous RPA during adolescence (12-17 years) and early adulthood (25-34 years), which were converted to total age-adjusted metabolic equivalents-per-week and categorized into quartiles. We conducted attained age analyses until age 40 (follow-up time began at age 18) using Cox proportional hazards regression models adjusted for study center, race and ethnicity, and education.

Results: Being in the highest versus lowest quartile of RPA during adolescence and early adulthood were respectively associated with 12% [HR (95% CI): 0.88 (0.78, 0.98)] and 16% [HR (95% CI): 0.84 (0.74, 0.95) lower BC risks before age 40. Being in the highest quartile of RPA during both adolescence and early adulthood (Pearson correlation=0.52) versus neither timepoint was associated with a 22% lower risk [HR (95% CI): 0.78 (0.68, 0.89)].

Conclusions: Findings suggest that RPA during adolescence and early adulthood may lower BC risk before age 40.

Impact: Policies promoting physical activity during adolescence and early adulthood may be important for reducing the growing burden of breast cancer in younger women.

背景:乳腺癌(BC)发病率在 40 岁以下女性中呈上升趋势,这说明有必要对年轻女性的乳腺癌风险因素进行研究:我们利用一个国际家庭队列(n=26,348)的数据,研究青春期和成年早期的娱乐性体育活动(RPA)是否与 40 岁前的乳腺癌风险有关。该队列包括 2,502 名在 40 岁前确诊患有乳腺癌的女性,其中 2,408 名在研究注册前确诊(68% 在注册后 5 年内)。女性报告了她们在青春期(12-17 岁)和成年早期(25-34 岁)每周中等强度和剧烈强度 RPA 的平均小时数,这些小时数被转换为每周经年龄调整的总代谢当量,并分为四等分。我们使用根据研究中心、种族和民族以及教育程度进行调整的 Cox 比例危险回归模型,对 40 岁(随访时间从 18 岁开始)之前的达到年龄进行了分析:在青春期和成年早期,RPA处于最高四分位数与最低四分位数分别与40岁前 BC风险降低12%[HR (95% CI):0.88 (0.78, 0.98)]和16%[HR (95% CI):0.84 (0.74, 0.95)]有关。在青春期和成年早期均处于RPA最高四分位数(Pearson correlation=0.52)与两个时间点均不处于RPA最高四分位数相比,风险降低22%[HR(95% CI):0.78 (0.68, 0.89)]:研究结果表明,青春期和成年早期的 RPA 可降低 40 岁前的 BC 风险:影响:促进青春期和成年早期体育锻炼的政策可能对减轻年轻女性日益加重的乳腺癌负担非常重要。
{"title":"Physical activity during adolescence and early adulthood and breast cancer risk before age 40 years.","authors":"Rebecca D Kehm, Jeanine M Genkinger, Julia A Knight, Robert J Maclnnis, Yuyan Liao, Shuai Li, Prue C Weideman, Wendy K Chung, Allison W Kurian, Sarah V Colonna, Irene L Andrulis, Saundra S Buys, Mary B Daly, Esther M John, John L Hopper, Mary Beth Terry","doi":"10.1158/1055-9965.EPI-24-0743","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0743","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) incidence is increasing in women under age 40 years, underscoring the need for research on BC risk factors for younger women.</p><p><strong>Methods: </strong>We used data from an international family cohort (n=26,348) to examine whether recreational physical activity (RPA) during adolescence and early adulthood are associated with BC risk before age 40. The cohort includes 2,502 women diagnosed with BC before age 40, including 2,408 diagnosed before study enrollment (68% within 5 years of enrollment). Women reported their average hours-per-week of moderate and strenuous RPA during adolescence (12-17 years) and early adulthood (25-34 years), which were converted to total age-adjusted metabolic equivalents-per-week and categorized into quartiles. We conducted attained age analyses until age 40 (follow-up time began at age 18) using Cox proportional hazards regression models adjusted for study center, race and ethnicity, and education.</p><p><strong>Results: </strong>Being in the highest versus lowest quartile of RPA during adolescence and early adulthood were respectively associated with 12% [HR (95% CI): 0.88 (0.78, 0.98)] and 16% [HR (95% CI): 0.84 (0.74, 0.95) lower BC risks before age 40. Being in the highest quartile of RPA during both adolescence and early adulthood (Pearson correlation=0.52) versus neither timepoint was associated with a 22% lower risk [HR (95% CI): 0.78 (0.68, 0.89)].</p><p><strong>Conclusions: </strong>Findings suggest that RPA during adolescence and early adulthood may lower BC risk before age 40.</p><p><strong>Impact: </strong>Policies promoting physical activity during adolescence and early adulthood may be important for reducing the growing burden of breast cancer in younger women.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers suitable for early detection of intrathoracic cancers in primary care: a systematic review. 适合基层医疗机构早期检测胸腔内癌症的生物标志物:系统综述。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-14 DOI: 10.1158/1055-9965.EPI-24-0713
Wasim Hamad, Bogdan Grigore, Hugo Walford, Jaime Peters, Panos Alexandris, Stefanie Bonfield, Laura Standen, Rachel Boscott, Dawnya Behiyat, Isla Kuhn, Richard D Neal, Fiona M Walter, Natalia Calanzani

Intrathoracic cancers, including lung cancer, mesothelioma, and thymoma, present diagnostic challenges in primary care. Biomarkers could resolve some challenges. We synthesized evidence on biomarkers performance for intrathoracic cancer detection in low-prevalence settings. A search in EMBASE and MEDLINE included studies that recruited participants with suspected intrathoracic cancer and reported on at least one diagnostic measure for a validated, non-invasive biomarker. Studies were excluded if participants were recruited based on a pre-established diagnosis. Fifty-two studies were included, reporting on 108 individual biomarkers and panels. CEA, CYFRA 21.1, and VEGF were evaluated for lung cancer and mesothelioma. For lung cancer, CEA and CYFRA 21.1 were most studied, with AUCs of 0.48-0.90 and 0.48-0.83, respectively. Pro-GRP and NSE had the highest NPVs (98.2%, 96.9%), while Early-CDT and MSC panels showed NPVs of 99.3% and 99.0% in smokers. For mesothelioma, Fibrillin-3 and mesothelin plus osteopontin had AUCs of 0.93 and 0.91, respectively. Thymoma panels (Binding AcHR + StrAb) and (Binding AcHR + Modulating AcHR + StrAb) had 100% NPVs in myasthenia gravis patients. The review highlights the performance of some biomarkers. However, few were evaluated in low-prevalence settings. Further evaluation is necessary before implementing these biomarkers for intrathoracic cancers in primary care.

胸腔内癌症,包括肺癌、间皮瘤和胸腺瘤,给初级医疗诊断带来了挑战。生物标志物可以解决一些难题。我们对生物标记物在低发病率环境下检测胸腔内癌症的性能证据进行了综合分析。我们在 EMBASE 和 MEDLINE 中检索了招募疑似胸腔内癌症患者并报告了至少一种经过验证的非侵入性生物标记物诊断指标的研究。如果参与者是根据预先确定的诊断结果招募的,则排除这些研究。共纳入 52 项研究,报告了 108 种生物标志物和生物标志物组。对肺癌和间皮瘤的 CEA、CYFRA 21.1 和血管内皮生长因子进行了评估。就肺癌而言,研究最多的是 CEA 和 CYFRA 21.1,其 AUC 分别为 0.48-0.90 和 0.48-0.83。Pro-GRP 和 NSE 的 NPV 值最高(98.2% 和 96.9%),而早期 CDT 和 MSC 面板在吸烟者中的 NPV 值分别为 99.3% 和 99.0%。对于间皮瘤,纤连蛋白-3 和间皮素加骨质素的 AUC 分别为 0.93 和 0.91。胸腺瘤试剂盒(结合AcHR + StrAb)和(结合AcHR + 调节AcHR + StrAb)在重症肌无力患者中的NPV为100%。综述强调了一些生物标记物的性能。然而,很少有生物标记物是在低发病率环境中进行评估的。在基层医疗机构对胸腔内癌症使用这些生物标记物之前,有必要进行进一步的评估。
{"title":"Biomarkers suitable for early detection of intrathoracic cancers in primary care: a systematic review.","authors":"Wasim Hamad, Bogdan Grigore, Hugo Walford, Jaime Peters, Panos Alexandris, Stefanie Bonfield, Laura Standen, Rachel Boscott, Dawnya Behiyat, Isla Kuhn, Richard D Neal, Fiona M Walter, Natalia Calanzani","doi":"10.1158/1055-9965.EPI-24-0713","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0713","url":null,"abstract":"<p><p>Intrathoracic cancers, including lung cancer, mesothelioma, and thymoma, present diagnostic challenges in primary care. Biomarkers could resolve some challenges. We synthesized evidence on biomarkers performance for intrathoracic cancer detection in low-prevalence settings. A search in EMBASE and MEDLINE included studies that recruited participants with suspected intrathoracic cancer and reported on at least one diagnostic measure for a validated, non-invasive biomarker. Studies were excluded if participants were recruited based on a pre-established diagnosis. Fifty-two studies were included, reporting on 108 individual biomarkers and panels. CEA, CYFRA 21.1, and VEGF were evaluated for lung cancer and mesothelioma. For lung cancer, CEA and CYFRA 21.1 were most studied, with AUCs of 0.48-0.90 and 0.48-0.83, respectively. Pro-GRP and NSE had the highest NPVs (98.2%, 96.9%), while Early-CDT and MSC panels showed NPVs of 99.3% and 99.0% in smokers. For mesothelioma, Fibrillin-3 and mesothelin plus osteopontin had AUCs of 0.93 and 0.91, respectively. Thymoma panels (Binding AcHR + StrAb) and (Binding AcHR + Modulating AcHR + StrAb) had 100% NPVs in myasthenia gravis patients. The review highlights the performance of some biomarkers. However, few were evaluated in low-prevalence settings. Further evaluation is necessary before implementing these biomarkers for intrathoracic cancers in primary care.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Subjects. 健康受试者血管组生物标志物随时间变化的生物学特性。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-14 DOI: 10.1158/1055-9965.EPI-24-0644
Yingmiao Liu, Jiatong Li, Jing Lyu, Lauren E Howard, Alexander B Sibley, Mark D Starr, John C Brady, Christy Arrowood, Elise C Kohn, S Percy Ivy, Herbert I Hurwitz, James L Abbruzzese, Kouros Owzar, Andrew B Nixon

Background: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in cancer patients, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants.

Methods: The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across 8 timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index (BMI), fasting status, and sampling factors.

Results: ICC was calculated to determine the reliability of each biomarker. HGF was the most stable marker (ICC=0.973), while PDGF-BB was the most variable marker (ICC=0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGF-1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL-6 (p=0.0114). Higher BMI was associated with higher levels of IL-6 (p=0.0003) and VEGF-R3 (p=0.0045).

Conclusions: Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay.

Impact: This data further supports the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.

背景:生物标志物分析是癌症研究不可或缺的一部分。尽管人们在识别和描述癌症患者的生物标志物方面付出了巨大努力,但对健康人群中生物标志物的自然变异却知之甚少。在此,我们进行了一项临床研究,以评估健康参与者体内生物标志物随时间的自然变化:血管组多重阵列是由 25 种循环蛋白生物标记物组成的小组,我们对 28 名健康参与者在 60 天内的 8 个时间点进行了评估。我们利用类内相关系数(ICC)来量化生物标记物的可靠性。在线性混合效应模型的框架下计算了调整后的 ICC 值,并考虑了年龄、性别、体重指数 (BMI)、空腹状态和取样因素:计算了 ICC 值,以确定每个生物标记物的可靠性。HGF是最稳定的标志物(ICC=0.973),而PDGF-BB则是变化最大的标志物(ICC=0.167)。总之,ICC 分析表明,25 个测量的生物标记物中有 22 个显示出良好(≥0.4)到卓越(>0.75)的 ICC 值。三个标记物(PDGF-BB、TGF-1、PDGF-AA)的 ICC 值为 结论:在短时间内测定的 25 种蛋白质生物标记物中,有 22 种标记物的 ICC 值为良好或极佳,为该生物标记物检测提供了更多验证:影响:这一数据进一步支持了血管组生物标志物测定的验证及其作为综合生物标志物在临床试验测试中的应用。
{"title":"Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Subjects.","authors":"Yingmiao Liu, Jiatong Li, Jing Lyu, Lauren E Howard, Alexander B Sibley, Mark D Starr, John C Brady, Christy Arrowood, Elise C Kohn, S Percy Ivy, Herbert I Hurwitz, James L Abbruzzese, Kouros Owzar, Andrew B Nixon","doi":"10.1158/1055-9965.EPI-24-0644","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0644","url":null,"abstract":"<p><strong>Background: </strong>Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in cancer patients, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants.</p><p><strong>Methods: </strong>The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across 8 timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index (BMI), fasting status, and sampling factors.</p><p><strong>Results: </strong>ICC was calculated to determine the reliability of each biomarker. HGF was the most stable marker (ICC=0.973), while PDGF-BB was the most variable marker (ICC=0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGF-1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL-6 (p=0.0114). Higher BMI was associated with higher levels of IL-6 (p=0.0003) and VEGF-R3 (p=0.0045).</p><p><strong>Conclusions: </strong>Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay.</p><p><strong>Impact: </strong>This data further supports the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers of Nicotine and Toxicant Exposure by E-liquid Nicotine Concentration Level among U.S. Adult Exclusive E-cigarette Users. 按电子烟液尼古丁浓度水平划分的美国成人电子烟使用者尼古丁和有毒物质暴露生物标志物。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1158/1055-9965.EPI-24-0955
Hongying Daisy Dai, Sara Reyes, James Buckley, Patrick Maloney

Background: The current e-cigarette market has been rapidly evolving with an increase in the share of high nicotine concentration vaping products. This study examined urinary biomarkers of exposure (BOEs) by nicotine concentration level among exclusive e-cigarette users.

Methods: Data were drawn from Wave 5 (December 2018-November 2019) of the Population Assessment of Tobacco and Health (PATH) Study. Between-subject differences in BOEs of nicotine, metal, tobacco-specific nitrosamine (TSNA), and volatile organic compounds (VOC) were examined across e-cigarettes containing nicotine or not (yes [n=300] vs. no [n=31] vs. non-tobacco use [n=3021]) and different nicotine concentration levels (0.1-1.7%, 1.8-4.9%, and 5.0%+).

Results: Among 3353 participants, exclusive e-cigarette users exhibited higher mean concentrations of nicotine metabolites than non-tobacco users. Nicotine e-cigarette users had higher concentrations of TNE2 (mean [95% CI]=21.8 [15.2-31.2] vs. 0.2 [0.1-0.6] nmol/mg creatinine, p<.0001) and cotinine (1418.2 [998.0-2015.4] vs. 12.2 [0.1-0.6], p<.0001) ng/mg creatinine, p<.0001) than non-nicotine e-cigarette users. Users of e-cigarette products with nicotine levels of 1.8-4.9% had higher TNE2 and cotinine levels than those using 0.1-1.7%, though differences were insignificant after adjusting for covariates. As compared to non-tobacco users, nicotine vapers had higher concentrations of lead (adjusted p=0.01).

Conclusions: Nicotine containing e-cigarette users exhibited elevated levels of nicotine metabolites than non-nicotine containing vapers and non-tobacco users. Future research needs to investigate health effects of e-cigarette use across different nicotine levels Impact: Regulating the nicotine content in e-cigarettes could be crucial in managing nicotine exposure and potentially mitigating associated health risks.

背景:目前的电子烟市场发展迅速,高尼古丁浓度的电子烟产品所占的份额越来越大。本研究按尼古丁浓度水平检测了电子烟独家使用者的尿液生物标志物暴露(BOEs):数据来自烟草与健康人群评估(PATH)研究的第 5 波(2018 年 12 月至 2019 年 11 月)。研究对象间尼古丁、金属、烟草特异性亚硝胺(TSNA)和挥发性有机化合物(VOC)的BOEs差异取决于电子烟是否含有尼古丁(含有[n=300] vs. 不含有[n=31] vs. 不使用烟草[n=3021])以及不同的尼古丁浓度水平(0.1%-1.7%、1.8%-4.9%和5.0%以上):结果:在3353名参与者中,专门使用电子烟者的尼古丁代谢物平均浓度高于非烟草使用者。尼古丁电子烟使用者的 TNE2 浓度更高(平均值[95% CI]=21.8 [15.2-31.2] vs. 0.2 [0.1-0.6] nmol/mg creatinine,pConclusions):与不含尼古丁的吸食者和非烟草使用者相比,含尼古丁的电子烟使用者的尼古丁代谢物水平较高。未来的研究需要调查不同尼古丁含量的电子烟对健康的影响:规范电子烟中的尼古丁含量对于管理尼古丁暴露和降低相关健康风险至关重要。
{"title":"Biomarkers of Nicotine and Toxicant Exposure by E-liquid Nicotine Concentration Level among U.S. Adult Exclusive E-cigarette Users.","authors":"Hongying Daisy Dai, Sara Reyes, James Buckley, Patrick Maloney","doi":"10.1158/1055-9965.EPI-24-0955","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0955","url":null,"abstract":"<p><strong>Background: </strong>The current e-cigarette market has been rapidly evolving with an increase in the share of high nicotine concentration vaping products. This study examined urinary biomarkers of exposure (BOEs) by nicotine concentration level among exclusive e-cigarette users.</p><p><strong>Methods: </strong>Data were drawn from Wave 5 (December 2018-November 2019) of the Population Assessment of Tobacco and Health (PATH) Study. Between-subject differences in BOEs of nicotine, metal, tobacco-specific nitrosamine (TSNA), and volatile organic compounds (VOC) were examined across e-cigarettes containing nicotine or not (yes [n=300] vs. no [n=31] vs. non-tobacco use [n=3021]) and different nicotine concentration levels (0.1-1.7%, 1.8-4.9%, and 5.0%+).</p><p><strong>Results: </strong>Among 3353 participants, exclusive e-cigarette users exhibited higher mean concentrations of nicotine metabolites than non-tobacco users. Nicotine e-cigarette users had higher concentrations of TNE2 (mean [95% CI]=21.8 [15.2-31.2] vs. 0.2 [0.1-0.6] nmol/mg creatinine, p<.0001) and cotinine (1418.2 [998.0-2015.4] vs. 12.2 [0.1-0.6], p<.0001) ng/mg creatinine, p<.0001) than non-nicotine e-cigarette users. Users of e-cigarette products with nicotine levels of 1.8-4.9% had higher TNE2 and cotinine levels than those using 0.1-1.7%, though differences were insignificant after adjusting for covariates. As compared to non-tobacco users, nicotine vapers had higher concentrations of lead (adjusted p=0.01).</p><p><strong>Conclusions: </strong>Nicotine containing e-cigarette users exhibited elevated levels of nicotine metabolites than non-nicotine containing vapers and non-tobacco users. Future research needs to investigate health effects of e-cigarette use across different nicotine levels Impact: Regulating the nicotine content in e-cigarettes could be crucial in managing nicotine exposure and potentially mitigating associated health risks.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alcohol consumption and smoking history at time of diagnosis, and risk of colorectal cancer recurrence and mortality: Results from the ColoCare Study. 诊断时的饮酒和吸烟史与结直肠癌复发和死亡风险:ColoCare 研究的结果。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-07 DOI: 10.1158/1055-9965.EPI-24-0834
Nicole C Loroña, Caroline Himbert, Jennifer Ose, Stacey A Cohen, Ildiko Strehli, Cornelia M Ulrich, Sofia Cobos, Esther Jean-Baptiste, Amanda M Bloomer, Jane C Figueiredo, Biljana Gigic, Sheetal Hardikar, Meghana Karchi, Matthew Mutch, Anita R Peoples, Martin Schneider, David Shibata, Erin M Siegel, Adetunji T Toriola, Elizabeth H Wood, Christopher I Li

Background: Findings from studies investigating the impacts of alcohol use and smoking on colorectal cancer (CRC) outcomes are inconclusive. This study aimed to investigate associations between alcohol use and smoking status at the time of diagnosis on recurrence and overall mortality among patients with CRC.

Methods: The present study included 2,216 stage I-IV patients with CRC from the longitudinal multi-center ColoCare study, with available data on recurrence and CRC-specific mortality. Cox proportional hazards models adjusted for age, sex, race, ethnicity, stage, tumor site, treatment, comorbidities, body mass index, and study site were fit, with imputations for missing data.

Results: We observed 235 recurrences and 308 CRC-specific deaths over an average of 3 years of follow-up. After adjusting for confounders, current alcohol consumption and ever smoking, relative to not current consumption and never smoking, respectively, were not statistically significantly associated with CRC recurrence (Alcohol - HR: 0.95. 95% CI: 0.71-1.29; Ever smoking - HR: 0.98, 95% CI: 0.75-1.29) or CRC-specific mortality (Alcohol - HR: 0.95. 95% CI: 0.74-1.22; Ever smoking - HR: 0.98, 95% CI: 0.77-1.24).

Conclusions: No associations were observed between alcohol and smoking at diagnosis and clinical outcomes in this well-annotated longitudinal cohort.

Impact: Our cohort study reports no significant associations; however, limiting alcohol use and avoiding smoking are health behaviors recommended for CRC survivors for prevention of other cancers and chronic conditions.

背景:有关饮酒和吸烟对结直肠癌(CRC)预后影响的研究结果尚无定论。本研究旨在调查确诊时饮酒和吸烟状况对 CRC 患者复发和总死亡率的影响:本研究纳入了 2,216 名 I-IV 期 CRC 患者,这些患者来自纵向多中心 ColoCare 研究,并提供了复发和 CRC 特异性死亡率数据。拟合了根据年龄、性别、种族、民族、分期、肿瘤部位、治疗、合并症、体重指数和研究地点进行调整的 Cox 比例危险模型,并对缺失数据进行了估算:在平均 3 年的随访中,我们观察到 235 例复发和 308 例 CRC 特异性死亡。在对混杂因素进行调整后,当前饮酒和曾经吸烟与当前未饮酒和从未吸烟相比,在统计学上与 CRC 复发无显著相关性(饮酒 - HR:0.95。95%CI:0.71-1.29;曾经吸烟 - HR:0.98,95%CI:0.75-1.29)或 CRC 特异性死亡率(酒精 - HR:0.95。95%CI:0.74-1.22;曾经吸烟--HR:0.98,95%CI:0.77-1.24):结论:在这一记录详实的纵向队列中,未观察到诊断时饮酒和吸烟与临床结果之间存在关联:我们的队列研究报告显示两者之间没有明显的关联;但是,为了预防其他癌症和慢性疾病,建议 CRC 幸存者限制饮酒和避免吸烟。
{"title":"Alcohol consumption and smoking history at time of diagnosis, and risk of colorectal cancer recurrence and mortality: Results from the ColoCare Study.","authors":"Nicole C Loroña, Caroline Himbert, Jennifer Ose, Stacey A Cohen, Ildiko Strehli, Cornelia M Ulrich, Sofia Cobos, Esther Jean-Baptiste, Amanda M Bloomer, Jane C Figueiredo, Biljana Gigic, Sheetal Hardikar, Meghana Karchi, Matthew Mutch, Anita R Peoples, Martin Schneider, David Shibata, Erin M Siegel, Adetunji T Toriola, Elizabeth H Wood, Christopher I Li","doi":"10.1158/1055-9965.EPI-24-0834","DOIUrl":"https://doi.org/10.1158/1055-9965.EPI-24-0834","url":null,"abstract":"<p><strong>Background: </strong>Findings from studies investigating the impacts of alcohol use and smoking on colorectal cancer (CRC) outcomes are inconclusive. This study aimed to investigate associations between alcohol use and smoking status at the time of diagnosis on recurrence and overall mortality among patients with CRC.</p><p><strong>Methods: </strong>The present study included 2,216 stage I-IV patients with CRC from the longitudinal multi-center ColoCare study, with available data on recurrence and CRC-specific mortality. Cox proportional hazards models adjusted for age, sex, race, ethnicity, stage, tumor site, treatment, comorbidities, body mass index, and study site were fit, with imputations for missing data.</p><p><strong>Results: </strong>We observed 235 recurrences and 308 CRC-specific deaths over an average of 3 years of follow-up. After adjusting for confounders, current alcohol consumption and ever smoking, relative to not current consumption and never smoking, respectively, were not statistically significantly associated with CRC recurrence (Alcohol - HR: 0.95. 95% CI: 0.71-1.29; Ever smoking - HR: 0.98, 95% CI: 0.75-1.29) or CRC-specific mortality (Alcohol - HR: 0.95. 95% CI: 0.74-1.22; Ever smoking - HR: 0.98, 95% CI: 0.77-1.24).</p><p><strong>Conclusions: </strong>No associations were observed between alcohol and smoking at diagnosis and clinical outcomes in this well-annotated longitudinal cohort.</p><p><strong>Impact: </strong>Our cohort study reports no significant associations; however, limiting alcohol use and avoiding smoking are health behaviors recommended for CRC survivors for prevention of other cancers and chronic conditions.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing 1 year Comorbidity Prevalence and Its Survival Implications in Medicare Beneficiaries Diagnosed with Cancer: Insights from a new SEER-Medicare Resource. 评估确诊癌症的医疗保险受益人的 1 年合并症患病率及其对生存的影响:从 SEER-Medicare 新资源中获得的启示。
IF 3.7 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-07 DOI: 10.1158/1055-9965.EPI-24-0833
Anne-Michelle Noone, Angela B Mariotto, Yoon Duk Hong, Lindsey Enewold

Background: Almost half of Medicare beneficiaries diagnosed with cancer from 1992-2005 had at least one comorbid condition. Conditions impact a range of domains from clinical decision making to quality of life which are important to consider when conducting cancer research. We introduce a new SEER-Medicare resource to facilitate using claims data for cancer patients.

Methods: We use the SEER-Medicare resource to estimate prevalence of comorbidities, 5-year survival rate by cancer site, stage, age and comorbidity severity, and prevalence of surgery by comorbidity for breast, prostate, colorectal and lung cancer.

Results: Overall, the most prevalent comorbidities in the year prior to cancer diagnosis were diabetes (27%), COPD (22%), peripheral vascular disease (14%), and congestive heart failure (12%). Comorbidity severity had a greater impact on the probability of dying from non-cancer causes than from dying from cancer. Severity of comorbidity and age consistently increased the probability of non-cancer death. The percentage of persons receiving surgery tended to be lower among those with severe comorbidity.

Conclusions: This study demonstrates the utility of new SEER*stat databases that contain Medicare beneficiaries and claims-based measures of comorbidity. Our results demonstrate that comorbidity is common among older persons diagnosed with cancer and the impact of comorbidity on the probability of dying from cancer varies by cancer site, stage at diagnosis and age.

Impact: Comorbidity is common among persons with cancer and impacts survival. Future research on the impact of comorbidity among cancer survivors is facilitated by new databases.

背景:1992-2005 年期间,近一半被诊断患有癌症的医疗保险受益人至少患有一种并发症。并发症会影响从临床决策到生活质量等一系列领域,这在进行癌症研究时是需要考虑的重要因素。我们介绍了一种新的 SEER-Medicare 资源,以方便使用癌症患者的索赔数据:我们利用 SEER-Medicare 资源估算了乳腺癌、前列腺癌、结直肠癌和肺癌的合并症患病率、按癌症部位、分期、年龄和合并症严重程度分类的 5 年生存率以及按合并症分类的手术率:总体而言,癌症确诊前一年最常见的合并症是糖尿病(27%)、慢性阻塞性肺病(22%)、外周血管疾病(14%)和充血性心力衰竭(12%)。与死于癌症相比,合并症严重程度对死于非癌症原因的概率影响更大。合并症的严重程度和年龄会持续增加非癌症死亡的概率。合并症严重者接受手术的比例往往较低:这项研究证明了新的 SEER*stat 数据库的实用性,该数据库包含医疗保险受益人和基于索赔的合并症测量指标。我们的研究结果表明,合并症在确诊癌症的老年人中很常见,合并症对癌症死亡概率的影响因癌症部位、确诊阶段和年龄而异:影响:合并症在癌症患者中很常见,会影响患者的生存。新的数据库有助于今后研究合并症对癌症幸存者的影响。
{"title":"Assessing 1 year Comorbidity Prevalence and Its Survival Implications in Medicare Beneficiaries Diagnosed with Cancer: Insights from a new SEER-Medicare Resource.","authors":"Anne-Michelle Noone, Angela B Mariotto, Yoon Duk Hong, Lindsey Enewold","doi":"10.1158/1055-9965.EPI-24-0833","DOIUrl":"10.1158/1055-9965.EPI-24-0833","url":null,"abstract":"<p><strong>Background: </strong>Almost half of Medicare beneficiaries diagnosed with cancer from 1992-2005 had at least one comorbid condition. Conditions impact a range of domains from clinical decision making to quality of life which are important to consider when conducting cancer research. We introduce a new SEER-Medicare resource to facilitate using claims data for cancer patients.</p><p><strong>Methods: </strong>We use the SEER-Medicare resource to estimate prevalence of comorbidities, 5-year survival rate by cancer site, stage, age and comorbidity severity, and prevalence of surgery by comorbidity for breast, prostate, colorectal and lung cancer.</p><p><strong>Results: </strong>Overall, the most prevalent comorbidities in the year prior to cancer diagnosis were diabetes (27%), COPD (22%), peripheral vascular disease (14%), and congestive heart failure (12%). Comorbidity severity had a greater impact on the probability of dying from non-cancer causes than from dying from cancer. Severity of comorbidity and age consistently increased the probability of non-cancer death. The percentage of persons receiving surgery tended to be lower among those with severe comorbidity.</p><p><strong>Conclusions: </strong>This study demonstrates the utility of new SEER*stat databases that contain Medicare beneficiaries and claims-based measures of comorbidity. Our results demonstrate that comorbidity is common among older persons diagnosed with cancer and the impact of comorbidity on the probability of dying from cancer varies by cancer site, stage at diagnosis and age.</p><p><strong>Impact: </strong>Comorbidity is common among persons with cancer and impacts survival. Future research on the impact of comorbidity among cancer survivors is facilitated by new databases.</p>","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Epidemiology Biomarkers & Prevention
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1